Director/PDMR Shareholding

December 14, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”)

Notification of transactions by person discharging managerial responsibilities

1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameBill Mordan
2.Reason for the notification
a)Position / statusGeneral Counsel and Company Secretary - PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionReceipt of ADSs following the vesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 26, 2016. In accordance with:

(i) the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, and the rules of the LTIP:

a. 100% of the PSUs vested pursuant to applicable performance conditions;

b. vesting of the PSUs was accelerated relative to the normal vesting date; and

(ii) the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the PSUs from the award date to the date of vesting. (Details of related disposal of ADSs are referenced in section 5. below.)
c)Price(s) and volume(s)Price(s)Volume(s)
$08,853
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionN/A
5.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the vesting of PSUs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the PSUs.
c)Price(s) and volume(s)Price(s)Volume(s)
$169.66253,983
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionNASDAQ


1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameJoanne Cordeiro
2.Reason for the notification
a)Position / statusChief Human Resources Officer – PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionReceipt of ADSs following the vesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on May 1, 2018.  In accordance with:

(i) the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, and the rules of the LTIP:

a. 100% of the PSUs vested pursuant to applicable performance conditions;

b. vesting of the PSUs was accelerated relative to the normal vesting date; and

(ii) the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the PSUs from the award date to the date of vesting.

(Details of related disposal of ADSs are referenced in section 5. below.)
c)Price(s) and volume(s)Price(s)Volume(s)
$012,050
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionN/A
5.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the vesting of PSUs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the PSUs.
c)Price(s) and volume(s)Price(s)Volume(s)
$169.66255,420
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionNASDAQ
6.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionReceipt of ADSs following the vesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 26, 2016.  In accordance with:

(i) the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, and the rules of the LTIP:

a. 100% of the PSUs vested pursuant to applicable performance conditions;

b. vesting of the PSUs was accelerated relative to the normal vesting date; and (ii) the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the PSUs from the award date to the date of vesting.
(Details of related disposal of ADSs are referenced in section 7. below.)
c)Price(s) and volume(s)Price(s)Volume(s)
$0494
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionN/A
7.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the vesting of PSUs referenced in section 6. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the PSUs.
c)Price(s) and volume(s)Price(s)Volume(s)
$169.6625224
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionNASDAQ
8.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionReceipt of ADSs following the vesting of Restricted Stock Units (“RSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on August 24, 2017.  In accordance with:

(i) the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, and the rules of the LTIP, vesting of the RSUs was accelerated relative to the normal vesting date; and (ii) the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the RSUs from the award date to the date of vesting.
(Details of related disposal of ADSs are referenced in section 9. below.)
c)Price(s) and volume(s)Price(s)Volume(s)
$01,410
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionN/A
9.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the vesting of RSUs referenced in section 8. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the RSUs.
c)Price(s) and volume(s)Price(s)Volume(s)
$169.6625633
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionNASDAQ
10.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionReceipt of ADSs following the vesting of Restricted Stock Units (“RSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 28, 2017.  In accordance with:

(i) the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, and the rules of the LTIP, vesting of the RSUs was accelerated relative to the normal vesting date; and (ii) the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the RSUs from the award date to the date of vesting.
(Details of related disposal of ADSs are referenced in section 11. below.)
c)Price(s) and volume(s)Price(s)Volume(s)
$0104
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionN/A
11.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the vesting of RSUs referenced in section 10. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the RSUs.
c)Price(s) and volume(s)Price(s)Volume(s)
$169.662547
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionNASDAQ
12.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionReceipt of ADSs following the vesting of Restricted Stock Units (“RSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 26, 2016.  In accordance with:

(i) the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, and the rules of the LTIP, vesting of the RSUs was accelerated relative to the normal vesting date; and (ii) the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the RSUs from the award date to the date of vesting.
 (Details of related disposal of ADSs are referenced in section 13. below.)
c)Price(s) and volume(s)Price(s)Volume(s)
$0173
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionN/A
13.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the vesting of RSUs referenced in section 12. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the RSUs.
c)Price(s) and volume(s)Price(s)Volume(s)
$169.662579
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionNASDAQ


1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NamePerry Sternberg
2.Reason for the notification
a)Position / statusHead of US Commercial - PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionReceipt of ADSs following the vesting of Restricted Stock Units (“RSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on August 5, 2016.  In accordance with:

(i) the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, and the rules of the LTIP, vesting of the RSUs was accelerated relative to the normal vesting date; and (ii) the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the RSUs from the award date to the date of vesting.
 (Details of related disposal of ADSs are referenced in section 5. below.)
c)Price(s) and volume(s)Price(s)Volume(s)
$01,011
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionN/A
5.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the vesting of RSUs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the RSUs.
c)Price(s) and volume(s)Price(s)Volume(s)
$169.6625388
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionNASDAQ
6.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionReceipt of ADSs following the vesting of Restricted Stock Units (“RSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 26, 2016.  In accordance with:

(i) the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, and the rules of the LTIP, vesting of the RSUs was accelerated relative to the normal vesting date; and (ii) the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the RSUs from the award date to the date of vesting.
 (Details of related disposal of ADSs are referenced in section 7. below.)
c)Price(s) and volume(s)Price(s)Volume(s)
$0441
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionN/A
7.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the vesting of RSUs referenced in section 6. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the RSUs.
c)Price(s) and volume(s)Price(s)Volume(s)
$169.6625133
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionNASDAQ
8.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionReceipt of ADSs following the vesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 26, 2016.  In accordance with:

(i) the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, and the rules of the LTIP:

a. 100% of the PSUs vested pursuant to applicable performance conditions;

b. vesting of the PSUs was accelerated relative to the normal vesting date; and

(ii) the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the PSUs from the award date to the date of vesting. (Details of related disposals of ADSs are referenced in sections 10. and 11. below.)
c)Price(s) and volume(s)Price(s)Volume(s)
$01,260
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionN/A
9.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionReceipt of ADSs following the vesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 28, 2017.  In accordance with:

(i) the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, and the rules of the LTIP:

a. 87% of the PSUs vested pursuant to applicable performance conditions;

b. vesting of the PSUs was accelerated relative to the normal vesting date; and

(ii) the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the PSUs from the award date to the date of vesting. (Details of related disposals of ADSs are referenced in sections 10. and 11. below.)
c)Price(s) and volume(s)Price(s)Volume(s)
$07,790
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionN/A
10.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the vesting of PSUs referenced in sections 8 and 9. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the PSUs.
c)Price(s) and volume(s)Price(s)Volume(s)
$169.66253,940
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionNASDAQ
11.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the vesting of PSUs referenced in sections 8. and 9. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the PSUs.
c)Price(s) and volume(s)Price(s)Volume(s)
$175.150091
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 13, 2018
f)Place of the transactionNASDAQ


1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameMatt Walker
2.Reason for the notification
a)Position / statusHead of Technical Operations – PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionReceipt of ADSs following the vesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on May 1, 2018.  In accordance with:

(i) the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, and the rules of the LTIP:

a. 100% of the PSUs vested pursuant to applicable performance conditions;

b. vesting of the PSUs was accelerated relative to the normal vesting date; and

(ii) the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the PSUs from the award date to the date of vesting. (Details of related disposal of ADSs are referenced in section 5. below.)
c)Price(s) and volume(s)Price(s)Volume(s)
$012,665
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionN/A
5.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the vesting of PSUs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the PSUs.
c)Price(s) and volume(s)Price(s)Volume(s)
$169.66255,652
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionNASDAQ
6.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionReceipt of ADSs following the vesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on May 2, 2016.  In accordance with:

(i) the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, and the rules of the LTIP:

a. 100% of the PSUs vested pursuant to applicable performance conditions;

b. vesting of the PSUs was accelerated relative to the normal vesting date; and

(ii) the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the PSUs from the award date to the date of vesting. (Details of related disposal of ADSs are referenced in section 7. below.)
c)Price(s) and volume(s)Price(s)Volume(s)
$03,292
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionN/A
7.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAutomated disposal of ADSs in relation to the vesting of PSUs referenced in section 6. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the PSUs.
c)Price(s) and volume(s)Price(s)Volume(s)
$169.6625983
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 11, 2018
f)Place of the transactionNASDAQ

Oliver Strawbridge
Senior Assistant Company Secretary

For further information please contact:

Investor Relations  
Christoph Brackmannchristoph.brackmann@shire.com+41 41 288 41 29
Sun Kimsun.kim@shire.com+1 617 588 8175
Scott Burrowsscott.burrows@shire.com+41 41 288 4195
   
Media  
Katie Joycekjoyce@shire.com +1 781 482 2779
   

NOTES TO EDITORS

About Shire

Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions. We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions. Relentlessly on the edge of what’s next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope. Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients. Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, and Ophthalmics.
 
Championing patients is our call to action - it brings the opportunity - and responsibility - to change people’s lives.

www.shire.com